LEADS BIOLABS-B(09887),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09887 LEADS BIOLABS-B

Closed 05-21 16:08:15

62.100

+1.550

+2.56%

High63.250	Low61.150	Vol654.86K
Open62.050	D1 Closing60.550	Amplitude3.47%
Mkt Cap12.36B	Tradable Cap9.50B	Total Shares199.00M
T/O40.63M	T/O Rate0.43%	Tradable Shares153.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":62.1,"timestamp":1779350895007,"preClose":60.55,"halted":0,"volume":654855,"delay":0,"changeRate":0.025598678777869602,"floatShares":153000000,"shares":199000000,"eps":-1.392520957051754,"marketStatus":"Closed","change":1.55,"latestTime":"05-21 16:08:15","open":62.05,"high":63.25,"low":61.15,"amount":40627601,"amplitude":0.034682,"askPrice":62.1,"askSize":8800,"bidPrice":62.05,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-1.3545431127685246,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779413400000},"marketStatusCode":5,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":60.55,"openAndCloseTimeList":[[1779327000000,1779336000000],[1779339600000,1779350400000]],"volumeRatio":0.87043,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09887/tweets","defaultTab":"tweets","newsList":[{"id":"1158348933","title":"Leads Biolabs to Spend up to US$50 Million on Trustee-Led H-Share Purchases for Employee Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1158348933","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158348933?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:22","pubTimestamp":1779276169,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has authorised the trustee of its H Share Award Scheme to buy additional H shares on the open market for an aggregate consideration of up to US$50.00...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153977350","title":"LEADS BIOLABS-B (09887) Authorizes Trustee to Acquire Up to $50 Million Worth of H Shares Under Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1153977350","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153977350?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:20","pubTimestamp":1779276036,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that the company has instructed the trustee to utilize plan funds, with a total maximum amount of $50 million, to acquire additional H shares through open market...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","09887","HK0000252160.HKD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636491018","title":"Nanjing Leads Biolabs Co Ltd - Instructs Trustee to Buy H Shares up to US$50 Mln Under H Share Award Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2636491018","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636491018?lang=en_us&edition=fundamental","pubTime":"2026-05-20 19:12","pubTimestamp":1779275565,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nFWN41X0MR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161159700","title":"LEADS BIOLABS-B Surges Over 4% in Morning Trading Following Phase III Clinical Trial Approval for Velishen™","url":"https://stock-news.laohu8.com/highlight/detail?id=1161159700","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161159700?lang=en_us&edition=fundamental","pubTime":"2026-05-19 10:24","pubTimestamp":1779157465,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) rose more than 4% in morning trading. As of the time of writing, the stock was up 3.21% to HK$64.35, with a turnover of HK$8.9751 million. On the news front, on May 19, LEADS...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VXUS","BK4134","BK4585","HK0000500386.USD","HK0000252152.HKD","III","09887","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150184251","title":"Leads Biolabs Gains CDE Green Light for Phase III Trial of PD-L1/4-1BB Bispecific Antibody in First-Line EP-NEC","url":"https://stock-news.laohu8.com/highlight/detail?id=1150184251","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150184251?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:22","pubTimestamp":1779146554,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. announced that China’s Center for Drug Evaluation has approved a randomized, double-blind, multi-centre Phase III study of Opamtistomig (LBL-024), a PD-L1/4-1BB...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160449247","title":"LEADS BIOLABS-B (09887): Phase 3 Trial for VELIXIN™ (PD-L1/4-1BB Bispecific Antibody Opatumilab) in Advanced Extrapulmonary Neuroendocrine Carcinoma Receives CDE Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1160449247","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160449247?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:22","pubTimestamp":1779146527,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has approved the initiation of a confirmatory Phase 3 clinical...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1223082196.USD","09887","LU1223083913.SGD","HK0000252160.HKD","CDE","HK0000252152.HKD","LU1223082519.USD","BK4017","PD","LU1169589451.USD","III","BK4023","HK0000500386.USD","BK4134","BK1161","LU1169590202.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636800242","title":"Nanjing Leads Biolabs wins China CDE clearance for LBL-024 Phase III EP-NEC trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636800242","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636800242?lang=en_us&edition=fundamental","pubTime":"2026-05-19 07:13","pubTimestamp":1779146008,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs secured clearance from China’s NMPA drug evaluator to start a confirmatory Phase III trial of Opamtistomig  with platinum chemotherapy as a first-line treatment for advanced extrapulmonary neuroendocrine carcinoma.The randomized, double-blind study follows Phase Ib/II results that the company plans to present at ESMO this year.A separate single-arm registrational study of Opamtistomig as a third-line-or-later monotherapy is slated for a BLA filing in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 18, 2026, and is solely re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL2pRr1R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","09887","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136090386","title":"Leads Biolabs Updates Board Composition and Committee Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=1136090386","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136090386?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:23","pubTimestamp":1778837016,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. disclosed the latest configuration of its Board of Directors and three specialised committees as of 15 May 2026. The Board now comprises nine members—three executive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101326531","title":"LEADS BIOLABS-B Finalises New Articles of Association: 198.89 Million Shares Authorised, Clearer Capital & Governance Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1101326531","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101326531?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:23","pubTimestamp":1778837006,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (“LEADS BIOLABS-B”) published its updated Articles of Association (effective May 2026), detailing the company’s capital structure, shareholder rights and governance...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104445964","title":"LEADS BIOLABS-B (09887): Dr. Wu Fenglan Appointed as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1104445964","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104445964?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:21","pubTimestamp":1778836877,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced the appointment of Dr. Wu Fenglan as a non-executive director of the company, effective from May 15, 2026, until the conclusion of the first board term. In...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635707543","title":"Nanjing Leads Biolabs files directors list with Hong Kong stock exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2635707543","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635707543?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:16","pubTimestamp":1778836579,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs filed updated board composition with Hong Kong Stock Exchange dated May 15, 2026.Executive directors listed as Xiaoqiang Kang, also chairman, CEO, general manager, Shoupeng Lai, Honggang Zuo.Non-executive directors listed as Yin Cheng Zhang, Renhai Chen, Fenglan Wu.Independent non-executive directors listed as Hongbing Zhang, Yilong Du, also lead independent non-executive director, Jiliu Du.Committee line-up showed Jiliu Du as audit committee chair, Hongbing Zhang as nomination committee chair, Yilong Du as remuneration committee chair.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Servic","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL3R8m8W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635707544","title":"Nanjing Leads Biolabs appoints Wu Fenglan non-executive director","url":"https://stock-news.laohu8.com/highlight/detail?id=2635707544","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635707544?lang=en_us&edition=fundamental","pubTime":"2026-05-15 17:16","pubTimestamp":1778836569,"startTime":"0","endTime":"0","summary":"Wu Fenglan was appointed non-executive director, effective May 15, 2026, following shareholder vote at annual general meeting.Appointment runs through expiry of first session of board, with re-election eligibility at a general meeting under company articles.Wu reported no other roles within group, no directorships at other listed companies in past three years, no share interests, no ties to directors, senior management, or major shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on May 15, 2026, and is solely responsible for the information contained","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL7pvF3v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","HK0000500386.USD","HK0000252160.HKD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178818679","title":"Leads Biolabs Gains HKEX Approval for Full H-Share Circulation, Converting 44.39 Million Unlisted Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1178818679","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178818679?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:22","pubTimestamp":1778764971,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that The Stock Exchange of Hong Kong Limited approved on 14 May 2026 the listing of 44.39 million newly-converted H shares, marking the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196445082","title":"LEADS BIOLABS-B Granted Listing Approval for H-Share Full Circulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1196445082","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196445082?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:14","pubTimestamp":1778764451,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B announced that the company has received approval from the Stock Exchange for the listing and trading of approximately 44.3916 million H shares, granted on May 14, 2026.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IPOS","HK0000252152.HKD","HK0000252160.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288039","title":"Leads Biolabs plans Q3 2026 China BLA filing for LBL-024 cancer antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288039","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634288039?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:03","pubTimestamp":1778497405,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs set a Q3 2026 filing target in China for LBL-024, a PD-L1/4-1BB bispecific antibody, positioning it as the company’s first potential commercial product with launch expected in 2027.Clinical results have already been generated across multiple studies, with reported outcomes highlighting a manageable safety profile and signs of broad activity in hard-to-treat tumors, including settings typically less responsive to checkpoint inhibitors.Additional readouts will be presented later in 2026, with first-line NSCLC data slated for WCLC in September.ESMO in October is expected to feature pivotal late-line extrapulmonary neuroendocrine carcinoma results, alongside updates in earlier-line disease and other tumor types.Regulatory momentum includes China Breakthrough Therapy Designation, US Fast Track and Orphan Drug designations, and EU Orphan Drug designation, supporting an accelerated path to market.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL803GJw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288796","title":"Leads Biolabs hosts R&D symposium in Shanghai on immuno-oncology strategy shift","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288796","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634288796?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:02","pubTimestamp":1778497375,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs held an R&D symposium in Shanghai under theme “Leads Innovation, Future Forward.”Management outlined a shift to multi-mechanism integration across its immuno-oncology platforms, flagged a first product launch in 2027, guided to 20+ clinical-stage molecules, 4 to 8 late-stage assets, and 3 commercial products by 2030.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via PR Newswire  on May 11, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nNDL9NtdkY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633450208","title":"Assessing Nanjing Leads Biolabs (SEHK:9887) Valuation After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450208","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633450208?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:56","pubTimestamp":1778244998,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs (SEHK:9887) has drawn fresh attention after recent trading left the stock with a month return of around a 10% decline, even as the past 3 months return stands near 28%.\nSee our latest analysis for Nanjing Leads Biolabs.\nThe latest 1 day share price return of 1.77% and 7 day share price return of 0.75% come after a 59.60% year to date share price gain. The 30 day share price return shows a 10.39% decline, which tempers what still looks like building momentum over the past...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-after-rec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9887/nanjing-leads-biolabs-shares/news/assessing-nanjing-leads-biolabs-sehk9887-valuation-after-rec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","HK0000252152.HKD","09887","HK0000500386.USD","HK0000252160.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127882981","title":"LEADS BIOLABS-B Receives CSRC Filing Notice for H Share Full Circulation and Plans to Implement the Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1127882981","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127882981?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:30","pubTimestamp":1778243428,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that, on behalf of 23 company shareholders, it submitted an application to the China Securities Regulatory Commission (CSRC) concerning the conversion of a total...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","09887","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176407072","title":"Leads Biolabs receives CSRC filing notice to convert 45.61 million unlisted shares into H shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1176407072","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176407072?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:25","pubTimestamp":1778243104,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that it has obtained a “Notification of filing on the ‘Full Circulation’ of Unlisted Shares” from the China Securities Regulatory Commission...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633568314","title":"Nanjing Leads Biolabs gets CSRC filing notice for H-share full circulation plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2633568314","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633568314?lang=en_us&edition=fundamental","pubTime":"2026-05-08 20:13","pubTimestamp":1778242432,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs received a China securities regulator filing notice covering conversion of 44,391,598 unlisted shares held by 23 shareholders into H shares under its H-share full circulation plan.Conversion and listing must be completed within 12 months of filing notice issuance date of April 27, 2026, or filing materials must be refreshed to proceed.Additional filing materials were submitted May 8, 2026 for conversion of 1,221,511 unlisted shares held by one shareholder into H shares.Next step is application to Hong Kong Stock Exchange for conversion and listing, subject to completion of required regulatory procedures.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content us","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nNDLpgbst:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","09887","HK0000500386.USD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.leadsbiolabs.com","stockEarnings":[{"period":"1week","weight":-0.1275},{"period":"1month","weight":-0.2951},{"period":"3month","weight":-0.0756},{"period":"6month","weight":0.1873},{"period":"1year","weight":0.73},{"period":"ytd","weight":0.1873}],"compareEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0395},{"period":"6month","weight":0.0171},{"period":"1year","weight":0.0832},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Nanjing Leads Biolabs Co Ltd is a China-based company primarily engaged in the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The company's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The Company has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The Company mainly conducts its business in the domestic market.","exchange":"SEHK","name":"LEADS BIOLABS-B","nameEN":"LEADS BIOLABS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LEADS BIOLABS-B(09887),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LEADS BIOLABS-B(09887) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LEADS BIOLABS-B,09887,LEADS BIOLABS-B股票,LEADS BIOLABS-B股票老虎,LEADS BIOLABS-B股票老虎国际,LEADS BIOLABS-B行情,LEADS BIOLABS-B股票行情,LEADS BIOLABS-B股价,LEADS BIOLABS-B股市,LEADS BIOLABS-B股票价格,LEADS BIOLABS-B股票交易,LEADS BIOLABS-B股票购买,LEADS BIOLABS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LEADS BIOLABS-B(09887),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LEADS BIOLABS-B(09887) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}